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Abstract 
Background: The purpose of this study was to describe the impact of an Advanced Practice Pharmacist (APh) on lowering hemoglobin 
A1c (HbA1c) in patients with type 2 diabetes within a patient centered medical home (PCMH) and to classify the types of therapeutic 
decisions made by the APh.  
Methods: This was a retrospective study using data from electronic health records. The study evaluated a partnership between 
Chapman University School of Pharmacy and Providence St. Joseph Heritage Healthcare that provided diabetes management by an 
Advanced Practice Pharmacist in a PCMH under a collaborative practice agreement. Change in the HbA1c was the primary endpoint 
assessed in this study. The type of therapeutic decisions made by the APh were also evaluated. Descriptive analysis and Wilcoxon signed 
rank test were used to analyze data.  
Results: The study included 35 patients with diagnosis of type 2 diabetes mellitus managed by an APh from May 2017 to December 
2017. Most of the patients were 60-79 years old (68.5%), 45.7% were female, and 45.7% were of Hispanic/Latino ethnicity. The average 
HbA1c was 8.8%±1.4% (range=6.0%-12.4%) and 7.5%±1.4% (range=5.5%-12.4%) at the initial and final APh visit, respectively 
(p<0.0001). Therapeutic decisions made by the APh included drug dose increase (35.5% of visits), drug added (16.4%), drug dose 
decrease (6.4%), drug switch (5.5%), and drug discontinuation (1.8%). 
Conclusion: The Advanced Practice Pharmacist’s interventions had a significant positive impact on lowering HbA1c in patients with 
type 2 diabetes mellitus in a PCMH. The most common therapeutic decisions made by the APh included drug dose increase and adding 
a new drug. 
Keywords: accountable care organization, collaborative practice agreement, diabetes, patient centered medical home, therapeutic 
decisions, advanced practice pharmacist 
 
 
Background 
According to the Centers for Disease Control (CDC), as of 2015, 
30.3 million people representing 9.4% of the US population 
have diabetes.1 Uncontrolled diabetes can lead to serious 
complications including an increased risk of cardiovascular 
disease such as heart attack and stroke. The optimization of 
patient care is imperative to prevent disease progression and 
the development of complications. Through collaborative 
practice agreements (CPAs), the clinical pharmacist can 
optimize care by providing chronic disease management and 
independently perform therapeutic interventions to improve 
quality of care and patient outcomes. 
Clinical pharmacists also play an important role in the patient 
centered medical home (PCMH). PCMH is a primary care 
delivery system with emphasis on multi-disciplinary team-
based care and inter-professional collaboration among 
healthcare providers.2-3 The PCMH care model aims to improve  
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the patient care experience and control cost through the 
provision of safe, high quality, evidence-based medicine.3 
Physicians have an average panel of about 2500 patients.4 As a 
result, physicians may not have enough time during a patient 
visit to manage chronic illnesses, diagnose acute illnesses, and 
maintain a positive relationship with their patients.4 Co-
management of patient panels by physicians, nurses, 
pharmacists and other PCMH team members allows for the 
expansion of primary care services and improvement in quality 
performance metrics.3 
Previous studies have looked at providers’ perception of 
pharmacy services in PCMH and how a pharmacist-physician 
collaboration for diabetes care can impact patient disease 
management.5-9 Providers consider pharmacists to be valuable 
and integral members of the health care team because the 
pharmacist can assist in patient management and improve 
quality as well as performance metrics.3,10-11 Other studies have 
evaluated the impact of pharmacist’s involvement on 
adherence in a team based model and how pharmacist’s 
involvement can lead to reducing drug and overall health care 
costs.12 Many studies concluded that a pharmacist’s 
involvement positively affects diabetes management and could 
reduce cost.12-24  
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In the state of California, pharmacists can hold the special 
designation of Advanced Practice Pharmacist (APh) if they 
satisfy certain criteria. The APh is authorized to perform patient 
assessments, refer patients to other health care providers and 
initiate, adjust, and discontinue drug therapy. The APh works 
upon referral from a patient’s treating provider and under a 
protocol. In addition, in collaboration with patient’s primary 
care physician (PCP), the APh can order and interpret drug 
therapy-related tests and participate in evaluation and 
management of patient’s health conditions. There are limited 
number of studies that describe the impact of Advanced 
Practice Pharmacists who practice as mid-level providers in a 
PCMH and who make decisions and medication adjustments 
independently under a CPA. 
The objectives of this study were to assess the impact of an APh 
working in a PCMH on reduction in the HbA1c values for 
patients with type 2 diabetes and to classify the types of 
therapeutic decisions made by the APh. 
Setting 
Providence St. Joseph Heritage Healthcare was founded in 
1994. It consists of 8 medical groups and supports six affiliated 
physician networks in California. There are approximately 175 
clinics, 915 medical group providers and 1,327 affiliate 
providers within Heritage. In May 2017, the administration at 
Providence St. Joseph Heritage Healthcare was interested in 
piloting a pharmacist-run, protocol-driven, disease state 
management (DSM) program at one of its clinics in Southern 
California, St. Jude Heritage Medical Group (SJHMG). At the 
time, this PCMH clinic consisted of 6 primary care providers 
(PCPs), one nurse practitioner (NP), one registered nurse (RN), 
and a case manager. The aim of the DSM program was to 
improve chronic care quality metrics, provide better access to 
care for patients and evaluate the impact of clinical pharmacy 
services on measures such as HbA1c. 
Although our study was a pilot study with only one APh 
pharmacist, currently, there are seven pharmacists practicing in 
PCMH clinics consisting of a team of 5-7 PCPs or family medicine 
physicians, and other health care providers. The team provides 
collaborative interdisciplinary care for patients. Most recently, 
a behavioral health provider was also added to the team in 
some clinics. The clinical pharmacists spend between 1 and 4 
days per week at the clinical practice site and attend daily 
multidisciplinary huddles. 
The clinical pharmacists are credentialed by the PCMH at 
Heritage. Due to the fast expansion of the pharmacy program 
in the last year, not all the pharmacists have a California 
Advanced Practice Pharmacist license; however, they plan to 
apply for this license in the immediate future. The clinical 
pharmacists work with physicians who are part of the PCMH 
under a CPA that includes management of type 2 diabetes, 
hypertension and dyslipidemia. The CPA excludes patients with 
type 1 and gestational diabetes. 
Physicians refer patients to the pharmacists who do not meet 
the American Diabetes Association (ADA) glycemic goal, as well 
as patients needing education about medications or lifestyle 
modification counselling. After obtaining the referral, the 
clinical pharmacist can independently initiate, modify and 
discontinue drug therapy; evaluate drug adherence; order and 
review lab values and vital signs; and recommend lifestyle 
modifications as needed. The office staff schedules the 
patients’ visits with the pharmacist and each pharmacist has 
her own schedule. Initial in-office pharmacist visits are 
scheduled for 1 hour and follow up in-office visits are scheduled 
for 30 minutes. The clinical pharmacists also manage patients 
via electronic patient portal or telephonically.  
Methods 
This was a retrospective study using electronic health records 
data. The study was conducted under a partnership between 
Chapman University School of Pharmacy and Providence St. 
Joseph Heritage Healthcare System. During the study period, 
one APh from Chapman University School of Pharmacy spent 1-
2 days per week in a PCMH clinic at Jude Heritage Medical 
Group and provided diabetes management under a CPA. The 
change in HbA1c pre and post APh management was the 
primary endpoint assessed in this study. APh was requested to 
show the value of the interventions within 6 months of starting 
the program. Thus, the change in HbA1c was considered an 
appropriate measure for detecting the effect of the 
interventions in the relatively short period of analysis. The 
study included patients diagnosed with diabetes mellitus type 
2 and referred to the clinical pharmacist regardless of HbA1c 
levels. Patients with type 1 and gestational diabetes were 
excluded from the study. A chart review was performed of each 
patient’s medical record. The data collected included patient 
demographics, number of APh visits, type of visit, and the 
HbA1c value at the first and successive APh visits. Information 
was also collected about APh’s interventions including adding a 
new drug, increasing or decreasing the dose of existing drugs, 
switching to a different drug, and discontinuing a drug. With the 
help of the Accountable Care Organization (ACO) partner, Blue 
Shield, and the administration at Heritage Healthcare, the APh 
pharmacist selected these types of interventions in order to 
best show the impact of APh presence within the PCMH model.  
Data collected were stored in password protected Microsoft 
Excel file, de-identified and saved in a secure computer. 
Microsoft Excel and IBM SPSS Statistics 25 software programs 
were used to analyze the data. Descriptive analysis and 
Wilcoxon signed rank test were used for the analysis. The effect 
size and post-hoc power analyses were performed using 
G*Power. Both Providence St. Joseph Heritage Healthcare and 
Chapman University IRB approvals were obtained prior to study 
initiation. 
Results 
The study included 35 patients who received comprehensive 
drug therapy management services for type 2 diabetes mellitus 
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by an APh in a St. Jude Heritage PCMH from May 2017 to 
December 2017. Patients’ ages ranged from 30-95 years, with 
68.5 % of patients between 60-79 years old. Female patients 
represented 45.7% of the patients and 45.7% of the patients 
were of Hispanic/Latino ethnicity (Table 1). 
The APh provided 110 visits; with an average ± standard 
deviation of 3.1±1.3 visits per patient (range 2-6 visits). Visits 
were conducted in-person (84.5%), over the phone (11.8%) or 
via a patient portal of the electronic medical record (3.6%). The 
average interval between each visit for patients was 100.4 
±53.6 days (median 84.0 days). 
The APh performed 72 therapeutic interventions with an 
average of 2.1±1.4 interventions per patient (range 0-5) and 
0.7±0.4 interventions per visit. The therapeutic interventions 
performed by the APh included dose increase (35.5% of visits), 
drug added to the patient’s regimen (16.4%), drug switch 
(5.5%), dose decrease (6.4%), and drug discontinuation (1.8%) 
(Table 2). The most common drugs involved in the APh 
therapeutic interventions were glimepiride (11.8%), glipizide 
(5.5%), insulin glargine (10.9%), and metformin (19.1%). 
The percentage of patients with a HbA1c value of >10.0% was 
14.3% and 2.8% pre and post intervention by the APh, 
respectively. The percentage of patients with elevated HbA1c 
values decreased, while the percentage of patients with lower 
HbA1c values increased pre and post intervention by the APh. 
(Table 3) The average ± standard deviation HbA1c changed 
from 8.8%±1.4% at baseline to 7.5%±1.4% at the last visit (Z=-
4.408, p<0.001). The effect size was large (d=0.93), indicating 
that the pre-post HbA1c difference was important. In addition, 
the result of post-hoc power analysis was large                                     
(1-beta=0.9994). Thus, we might assume that the intervention 
by APh caused a significant reduction in HbA1c. Changes in 
HbA1c values varied by patient (Table 4). There were 24 (68.6%) 
patients that experienced an HbA1c reduction, 18 (51.4%) 
patients that had an absolute HbA1c reduction of at least 1.0% 
and 15 (42.9%) patients that achieved an HbA1c level ≤7.0% at 
the end of the study. 
Discussion 
This study demonstrated the impact of an APh providing care 
to patients with type 2 diabetes under a CPA in a PCMH. The 
study found a significant reduction in HbA1c post APh 
intervention and it discerned the type of therapeutic decisions 
that the APh adopted during patient visits.  
Previous studies also found positive effects of pharmacists’ 
interventions in diabetes care outcomes. A meta-analysis of 14 
clinical trials found that pharmacist interventions resulted in a 
HbA1c reduction of 1.36%±1.53% (95% CI: 0.83%-1.89%) in type 
1 and type 2 diabetes patients.25 Another meta-analysis 
including 22 studies found that pharmacists interventions in 
outpatient clinics resulted in a reduction of 0.85% in HbA1c 
(95% CI: 0.65%-1.06%, p < 0.0001) in type 2 diabetes patients.26  
Furthermore, another study found a large HbA1c reduction in 
patients who enrolled in the pharmacist-management group 
compared to usual care.27  
In our study, the APh made independent therapeutic decisions 
during patient visits. The primary care physicians at the clinic 
did not change any of the therapeutic decisions made by the 
APh. Several other studies have also shown that pharmacists 
working under a collaborative practice agreement are well 
accepted by physicians in group practice settings.28,29 
While cost was not assessed in this study, previous studies 
demonstrated that pharmacists are cost-effective in managing 
diabetes in collaborative care programs.30 A previous study 
compared patients who achieved and did not achieve a 
decrease in HbA1c and found that patients with a decrease in 
HbA1c had 24% and 17% lower average annual healthcare costs 
during the first and second year of follow up, respectively. 31  
In addition to other outcome measures, Blue Shield, our ACO 
partner, has contracted measures on HbA1c reduction for 
patients. Thus, this pilot study was important to show that APh 
engagement can help improve performance metrics.  
Our study found that the two most common therapeutic 
decisions made by the APh were drug dose increase and adding 
a new drug to the patient’s regimen. Other therapeutic 
decisions included drug dose decrease, drug switch, and drug 
discontinuation. Those decisions may explain the reduction in 
HbA1c observed in this study. 
The results of our study confirm the positive impact of the APh 
on diabetes care outcomes. The utilization of pharmacists to 
manage patients with complex chronic diseases not only 
improves patient outcomes, but it may also help to address the 
current shortage of primary care physicians.32  
There were 10 patients who did not have a reduction in HbA1c 
values. These patients had varying levels of HbA1c and we did 
not observe a pattern related to the number of visits, number 
of interventions, and type of interventions these patients had 
in relation to patients who exhibited a change in HbA1c. 
Although the pharmacist intervention did not result in the 
HgA1c reduction for 10 patients, it is important to note that 
these patients also did not see an increase in HbA1c. Future 
analysis should evaluate factors that explain why some patients 
do not experience a reduction in HbA1c levels.  
There were 3 patients who received counseling and had their 
medications reviewed by the APh and who did not have any 
change in therapy. These patients also experienced a reduction 
in HbA1c. Future studies should assess the separate effects of 
APh's medication review and patient counseling on diabetes 
health outcomes. 
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This study has some limitations. The study included a limited 
number of patients; however, differences in the primary 
outcome of the analysis were statistically significant with 
enough power to detect differences in the study outcome. An 
ongoing study with participation of additional clinical 
pharmacists is currently being conducted. While patients were 
asked and educated about adverse events such as 
hypoglycemia at each visit with the APh, we did not track these 
outcomes.  Our study also did not track APh lifestyle 
modifications counseling interventions. Some patients may be 
able to lower their HbA1c values with diet and exercise alone 
and without medications or medication changes. The period of 
analysis was relatively short, but enough to demonstrate 
significant results and justify the expansion of the clinical 
pharmacist program.  
 
Conclusions 
An Advanced Practice Pharmacist led comprehensive type-2 
diabetes management program under a collaborative practice 
agreement in a patient-centered medical home resulted in 
improvement in HbA1c values.  Changes in drug therapy, 
including drug dose increase and adding a new medication were 
the most common interventions made. APh pharmacists are a 
valuable part of the interprofessional health care team.  
 
 
 
Key Points  
 Advanced Practice Pharmacist is an integral part of an 
inter-professional team within a patient centered medical 
home.   
 Independent therapeutic decision making by an Advanced 
Practice Pharmacist can improve HbA1c values.   
 Pharmacist led chronic disease management is an 
important part of health care delivery within a health 
system.   
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Table 1. Patient Demographics 
 
Parameters   Patients, n (%) 
Age groups (years) 
30-39  
40-49 
50-59 
60-69 
70-79 
80+ 
Total 
 
  1 (2.9%) 
  3 (8.6%) 
  6 (17.1%) 
13 (37.1%) 
11 (31.4%) 
  1 (2.9%) 
35 (100.0) 
Sex 
 Female 
 Male 
 
16 (45.7 %) 
19 (54.3%) 
Race 
Asian 
Black or African 
Native Hawaiian 
Patient Declined 
Two or more Races 
White 
 
  2 (5.7%) 
  1 (2.9%) 
  1 (2.9%) 
  1 (2.9%) 
  4 (11.4%) 
26 (74.3%) 
Ethnicity 
Hispanic or Latino 
Non-Hispanic or Latino 
Patient Declines 
 
 
16 (45.7%) 
16 (45.7%) 
   
3 (8.6%) 
BMI 
25.0-29.9 
30-35.9 
36 + 
Unknown  
 
10 (28.6 %) 
8 (22.9 %) 
9 (25.7%) 
8 (22.9%) 
Pharmacist interventions (n)/ 
Patient over multiple visits 
   2 
   3 
   4 
   5 
   6 
 
 
 
16 (45.7%) 
10 (28.6%) 
  5 (14.3%) 
  1 (2.9%) 
  3 (8.6%) 
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Table 2. Clinical Pharmacist Therapeutic Interventions 
 and Antidiabetic Drugs Involved 
Parameters Value, n (%) 
Type of Interventions 
Dose increase 
Drug added 
Dose decrease 
Drug switch 
Drug discontinuation 
 
 
39 (35.5 %) 
18 (16.4 %) 
7 (6.4 %) 
6 (5.5 %) 
2 (1.8 %) 
Drugs  
metformin 
glimepiride 
insulin glargine 
glipizide 
insulin degludec 
exenatide 
glyburide 
sitagliptin 
 
21 (19.1%) 
13 (11.8%) 
12 (10.9%) 
6 (5.5%)  
1 (0.9%) 
1 (0.9%) 
1 (0.9%) 
1 (0.9%) 
 
 
 
 
Table 3. Hemoglobin A1c levels Pre and Post intervention 
Parameters  Pre intervention 
n (%) 
Post intervention 
n (%) 
HbA1c range 
<6% 
6-6.9% 
7-7.9% 
8-8.9% 
9-9.9% 
>10%, 
Total 
Average* ±SD 
Range 
95%CI 
 
 
0 
3 (8.6%) 
6 (17.1%) 
10 (28.6%) 
11 (31.4%) 
5 (14.3%) 
35 (100.0)% 
8.8%±1.4% 
6.0%-12.4% 
8.3%-9.3% 
 
2 (5.7%) 
15(42.9%) 
9 (25.7%) 
3 (8.6%) 
5 (14.3%) 
1(2.8%) 
35 (100.0)% 
7.5% ±1.4% 
5.5%-12.4% 
7.0%-8.0% 
HbA1c = glycosylated hemoglobin 
*p<0.0001 
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Table 4. Pre and Post Intervention Hemoglobin A1c Levels, Visits and Therapeutic Interventions 
Patient 
Pre 
HbA1c 
Post 
HbA1c 
Pre-Post 
HbA1c 
Difference 
Number 
of Visits 
Number of 
Interventions 
Type of Intervention (Number) 
1 6.00% 6.20% -0.20% 3 1 drug added (1) 
2 6.60% 6.60% 0.00% 4 1 dose decrease (1) 
3 6.80% 6.80% 0.00% 4 1 dose increased (1) 
4 7.30% 6.50% 0.80% 2 2 
dose increased (1), drug discontinue 
(1)  
5 7.50% 6.90% 0.60% 2 0 none 
6 7.70% 7.60% 0.10% 2 1 dose increased (1) 
7 7.70% 7.70% 0.00% 3 2 dose increased (2) 
8 7.80% 7.80% 0.00% 5 4 dose increased (2), dose decrease (2) 
9 7.90% 6.50% 1.40% 3 1 drug added (1) 
10 8.00% 6.40% 1.60% 4 1 drug added (1) 
11 8.00% 7.00% 1.00% 2 1 drug added (1) 
12 8.10% 7.50% 0.60% 6 5 dose increased (3), drug added (2) 
13 8.10% 8.10% 0.00% 2 1 drug added (1) 
14 8.20% 8.20% 0.00% 2 0 none 
15 8.50% 6.80% 1.70% 2 1 drug added (1) 
16 8.50% 7.10% 1.40% 2 3 dose increased (2), drug added (1) 
17 8.60% 5.90% 2.70% 6 3 dose increased (2), drug switch (1) 
18 8.80% 6.70% 2.10% 5 4 
dose increased (1), dose decrease (1), 
drug switch (2) 
19 8.80% 5.50% 3.30% 2 1 drug discontinue (1) 
20 9.00% 6.70% 2.30% 3 2 dose increased (1), drug added (1) 
21 9.20% 6.80% 2.40% 2 1 dose increased (1) 
22 9.20% 9.20% 0.00% 2 1 drug added (1) 
23 9.20% 6.70% 2.50% 3 2 dose increased (2) 
24 9.40% 7.90% 1.50% 3 4 
dose increased (2), drug added (1), 
dose decrease (1) 
25 9.40% 9.40% 0.00% 2 1 dose increased (1) 
26 9.40% 7.90% 1.50% 3 2 dose increased (2) 
27 9.50% 7.10% 2.40% 4 0 none 
28 9.60% 6.00% 3.60% 2 2 dose increased (1), dose decrease (1) 
29 9.60% 9.20% 0.40% 3 3 dose increased (2), drug switch (1) 
30 9.90% 9.90% 0.00% 2 3 dose increased (2), drug switch (1) 
31 10.10% 9.50% 0.60% 3 4 dose increased (2), drug added (2) 
32 10.20% 8.30% 1.90% 4 3 dose increased (1), drug added (2) 
33 12.10% 6.70% 5.40% 6 5 
dose increased (1), drug added (2), 
 drug switch (1), dose decrease (1) 
34 12.10% 6.10% 6.00% 3 2 dose increased (2) 
35 12.40% 12.40% 0.00% 4 4 dose increased (4) 
 
